Clinical trial
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable…
NCT00250796 · University of New Mexico, Other · Completed
Key facts
| NCT number | NCT00250796 |
|---|---|
| Title | Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma |
| Official title | Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma |
| Lead sponsor | University of New Mexico, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver, Cancer |
| Intervention type | Drug |
| Interventions | Thalidomide, alpha interferon, interferon, Octreotide |
| Enrollment | 12 |
| Start date | Sep 1, 2000 |
| Primary completion | Jan 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Nov 8, 2005 |
| Last update posted | Jan 7, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: